{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:11:53Z","timestamp":1792289513682,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10787-018-00557-2","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T05:11:49Z","timestamp":1546405909000},"page":"911-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["International multicenter randomized, placebo-controlled phase III clinical trial of \u03b2-d-mannuronic acid in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-7999","authenticated-orcid":false,"given":"Zahra","family":"Rezaieyazdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Soleymani-Salehabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3607-0118","authenticated-orcid":false,"given":"Arman","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Aslani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiedeh","family":"Omidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Sadoughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Vahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-1783","authenticated-orcid":false,"given":"Mandana","family":"Khodashahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Zamurrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-4669","authenticated-orcid":false,"given":"Seyed Shahabeddin","family":"Mortazavi-Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Fallahzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Aghazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin","family":"Ekhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4619-9874","authenticated-orcid":false,"given":"Hidenori","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd H. A.","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6131-3690","authenticated-orcid":false,"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-5558","authenticated-orcid":false,"given":"Antimo","family":"D\u2019Aniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-2747","authenticated-orcid":false,"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"557_CR1","first-page":"433","volume":"16","author":"H Ahmadi","year":"2017","unstructured":"Ahmadi H, Jamshidi AR, Mahmoudi M et al (2017) Hematological improvement of patients with active rheumatoid arthritis by \u03b2-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property. Iran J Allergy Asthma Immunol 16:433\u2013442","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"557_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10787-018-0475-z","volume":"26","author":"H Ahmadi","year":"2018","unstructured":"Ahmadi H, Jamshidi AR, Gharibdoost F et al (2018a) A phase I\/II randomized, controlled, clinical trial for assessment of the efficacy and safety of \u03b2-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology 26:737\u2013745. \n                    https:\/\/doi.org\/10.1007\/s10787-018-0475-z","journal-title":"Inflammopharmacology"},{"key":"557_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10787-017-0410-8","volume":"26","author":"H Ahmadi","year":"2018","unstructured":"Ahmadi H, Mahmoudi M, Gharibdoost F et al (2018b) Targeting of circulating Th17 cells by \u03b2-d-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. Inflammopharmacology 26:57\u201365. \n                    https:\/\/doi.org\/10.1007\/s10787-017-0410-8","journal-title":"Inflammopharmacology"},{"key":"557_CR4","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581. \n                    https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"557_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/sji.12519","volume":"85","author":"S Aletaha","year":"2017","unstructured":"Aletaha S, Haddad L, Roozbehkia M et al (2017) M2000 (\u03b2-d-mannuronic acid) as a novel antagonist for blocking the TLR 2 and TLR 4 downstream signalling pathway. Scand J Immunol 85:122\u2013129. \n                    https:\/\/doi.org\/10.1111\/sji.12519","journal-title":"Scand J Immunol"},{"key":"557_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1533317516678086","volume":"32","author":"S Athari Nik Azm","year":"2017","unstructured":"Athari Nik Azm S, Vafa M, Sharifzadeh M et al (2017) Effects of M2000 (D-mannuronic acid) on learning, memory retrieval, and associated determinants in a rat model of Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen 32:12\u201321. \n                    https:\/\/doi.org\/10.1177\/1533317516678086","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"557_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/DDDT.S129419","volume":"11","author":"A Barati","year":"2017","unstructured":"Barati A, Jamshidi AR, Ahmadi H et al (2017) Effects of \u03b2-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, ROR\u03b3t, IL4 and GATA3 gene expressions in rheumatoid arthritis patients. Drug Des Devel Ther 11:1027\u20131033. \n                    https:\/\/doi.org\/10.2147\/DDDT.S129419","journal-title":"Drug Des Devel Ther"},{"issue":"737\u2013743","key":"557_CR8","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1016\/j.jaip.2016.12.006","volume":"5","author":"KG Blumenthal","year":"2017","unstructured":"Blumenthal KG, Lai KH, Huang M et al (2017) Adverse and hypersensitivity reactions to prescription nonsteroidal anti-inflammatory agents in a large health care system. J Allergy Clin Immunol Pract 5(737\u2013743):e733. \n                    https:\/\/doi.org\/10.1016\/j.jaip.2016.12.006","journal-title":"J Allergy Clin Immunol Pract"},{"key":"557_CR9","first-page":"175","volume":"36","author":"E Calabresi","year":"2018","unstructured":"Calabresi E, Petrelli F, Bonifacio A et al (2018) One year in review 2018: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 36:175\u2013184","journal-title":"Clin Exp Rheumatol"},{"key":"557_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","volume":"31","author":"KD Deane","year":"2017","unstructured":"Deane KD, Demoruelle MK, Kelmenson LB et al (2017) Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol 31:3\u201318. \n                    https:\/\/doi.org\/10.1016\/j.berh.2017.08.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"557_CR11","first-page":"443","volume":"16","author":"MM Farahani","year":"2017","unstructured":"Farahani MM, Motevaseli E, Maghsood F et al (2017) Anti-inflammatory property of \u03b2-d-mannuronic acid (M2000) on expression and activity of matrix metalloproteinase-2 and-9 through CD147 molecule in phorbol myristate acetate-differentiated THP-1 cells. Iran J Allergy Asthma Immunol 16:443\u2013451","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"557_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3109\/08923973.2015.1113296","volume":"37","author":"MJ Fattahi","year":"2015","unstructured":"Fattahi MJ, Abdollahi M, Agha Mohammadi A et al (2015) Preclinical assessment of \u03b2-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol 37:535\u2013540. \n                    https:\/\/doi.org\/10.3109\/08923973.2015.1113296","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"557_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biopha.2018.02.059","volume":"100","author":"MJ Fattahi","year":"2018","unstructured":"Fattahi MJ, Ahmadi H, Jafarnezhad-Ansariha F et al (2018a) Oral administration effects of \u03b2-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. Biomed Pharmacother 100:495\u2013500. \n                    https:\/\/doi.org\/10.1016\/j.biopha.2018.02.059","journal-title":"Biomed Pharmacother"},{"key":"557_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2017.11.003","volume":"54","author":"MJ Fattahi","year":"2018","unstructured":"Fattahi MJ, Jamshidi AR, Mahmoudi M et al (2018b) Evaluation of the efficacy and safety of \u03b2-d-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I\/II clinical trial. Int Immunopharmacol 54:112\u2013117. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2017.11.003","journal-title":"Int Immunopharmacol"},{"key":"557_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729\u2013740","journal-title":"Arthritis Rheum"},{"key":"557_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"key":"557_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity 46:183\u2013196. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2017.02.006","journal-title":"Immunity"},{"key":"557_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13063-017-2396-3","volume":"19","author":"L Hartman","year":"2018","unstructured":"Hartman L, Rasch LA, Klausch T et al (2018) Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials 19:67. \n                    https:\/\/doi.org\/10.1186\/s13063-017-2396-3","journal-title":"Trials"},{"key":"557_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1515\/jbcpp-2016-0092","volume":"28","author":"S Hosseini","year":"2017","unstructured":"Hosseini S, Abdollahi M, Azizi G et al (2017) Anti-aging effects of M2000 (\u03b2-d-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model. J Basic Clin Physiol Pharmacol 28:249\u2013255. \n                    https:\/\/doi.org\/10.1515\/jbcpp-2016-0092","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"557_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2174\/1871530318666180418111354","volume":"18","author":"M Jahanbakhshi","year":"2018","unstructured":"Jahanbakhshi M, Babaloo Z, Mortazavi-Jahromi SS et al (2018) Modification of sexual hormones in rheumatoid arthritis patients by M2000 (\u03b2-d-mannuronic acid) as a Novel NSAID with immunosuppressive property. Endocr Metab Immune Disord Drug Targets 18:530\u2013536. \n                    https:\/\/doi.org\/10.2174\/1871530318666180418111354","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"557_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5114\/reum.2018.76816","volume":"56","author":"J Ko\u0142odziejska","year":"2018","unstructured":"Ko\u0142odziejska J, Ko\u0142odziejczyk M (2018) Diclofenac in the treatment of pain in patients with rheumatic diseases. Reumatologia 56:174\u2013183. \n                    https:\/\/doi.org\/10.5114\/reum.2018.76816","journal-title":"Reumatologia"},{"key":"557_CR22","first-page":"105","volume":"10","author":"A Mirshafiey","year":"2004","unstructured":"Mirshafiey A, Khorramizadeh MR, Saadat F et al (2004) Chemopreventive effect of M2000, a new anti-inflammatory agent. Med Sci Monit 10:105\u2013109","journal-title":"Med Sci Monit"},{"key":"557_CR23","first-page":"Pl53","volume":"11","author":"A Mirshafiey","year":"2005","unstructured":"Mirshafiey A, Cuzzocrea S, Rehm B et al (2005a) M2000: a revolution in pharmacology. Med Sci Monit 11:Pl53\u2013Pl63","journal-title":"Med Sci Monit"},{"key":"557_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-3083.2005.01594.x","volume":"61","author":"A Mirshafiey","year":"2005","unstructured":"Mirshafiey A, Cuzzocrea S, Rehm B et al (2005b) Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand J Immunol 61:435\u2013441. \n                    https:\/\/doi.org\/10.1111\/j.1365-3083.2005.01594.x","journal-title":"Scand J Immunol"},{"key":"557_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1081\/IPH-200067751","volume":"27","author":"A Mirshafiey","year":"2005","unstructured":"Mirshafiey A, Matsuo H, Nakane S et al (2005c) Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol 27:255\u2013265","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"557_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.etap.2007.02.002","volume":"24","author":"A Mirshafiey","year":"2007","unstructured":"Mirshafiey A, Rehm B, Abhari RS et al (2007a) Production of M2000 (\u03b2-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol 24:60\u201366. \n                    https:\/\/doi.org\/10.1016\/j.etap.2007.02.002","journal-title":"Environ Toxicol Pharmacol"},{"key":"557_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/08923970701282387","volume":"29","author":"A Mirshafiey","year":"2007","unstructured":"Mirshafiey A, Rehm B, Sotoude M et al (2007b) Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immunotoxicol 29:49\u201361","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"557_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.pharep.2017.04.015","volume":"69","author":"A Mirshafiey","year":"2017","unstructured":"Mirshafiey A, Taeb M, Mortazavi-Jahromi SS et al (2017) Introduction of \u03b2-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1\/COX-2 activity and gene expression. Pharmacol Rep 69:1067\u20131072. \n                    https:\/\/doi.org\/10.1016\/j.pharep.2017.04.015","journal-title":"Pharmacol Rep"},{"key":"557_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.pharep.2017.01.021","volume":"69","author":"SS Mortazavi-Jahromi","year":"2017","unstructured":"Mortazavi-Jahromi SS, Jamshidi MM, Farazmand A et al (2017) Pharmacological effects of \u03b2-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-\u03baB gene expression, as target molecules in inflammatory reactions. Pharmacol Rep 69:479\u2013484. \n                    https:\/\/doi.org\/10.1016\/j.pharep.2017.01.021","journal-title":"Pharmacol Rep"},{"key":"557_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2018.1481094","author":"SS Mortazavi-Jahromi","year":"2018","unstructured":"Mortazavi-Jahromi SS, Alizadeh S, Javanbakht MH et al (2018a) Anti-diabetic effect of \u03b2-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model. Arch Physiol Biochem. \n                    https:\/\/doi.org\/10.1080\/13813455.2018.1481094","journal-title":"Arch Physiol Biochem"},{"key":"557_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/08923973.2018.1455209","volume":"40","author":"SS Mortazavi-Jahromi","year":"2018","unstructured":"Mortazavi-Jahromi SS, Alizadeh S, Javanbakht MH et al (2018b) Cardioprotective effect of \u03b2-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model. Immunopharmacol Immunotoxicol 40:284\u2013289. \n                    https:\/\/doi.org\/10.1080\/08923973.2018.1455209","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"557_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.1780261107","volume":"26","author":"T Pincus","year":"1983","unstructured":"Pincus T, Summey JA, Soraci SA Jr et al (1983) Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346\u20131353","journal-title":"Arthritis Rheum"},{"key":"557_CR33","first-page":"8","volume":"9","author":"F Pourgholi","year":"2017","unstructured":"Pourgholi F, Hajivalili M, Razavi R et al (2017) The role of M2000 as an anti-inflammatory agent in toll-like receptor 2\/microRNA-155 pathway. Avicenna J Med Biotechnol 9:8\u201312","journal-title":"Avicenna J Med Biotechnol"},{"key":"557_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"M Prevoo","year":"1995","unstructured":"Prevoo M, Van\u2019T Hof MA, Kuper H et al (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"557_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/1440-1681.12907","volume":"45","author":"M Rastegari-Pouyani","year":"2018","unstructured":"Rastegari-Pouyani M, Mostafaie A, Mansouri K et al (2018) Anti-angiogenesis effect of \u03b2-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model. Clin Exp Pharmacol Physiol 45:370\u2013376. \n                    https:\/\/doi.org\/10.1111\/1440-1681.12907","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"557_CR36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00296-016-3649-2","volume":"37","author":"Y-K Sung","year":"2017","unstructured":"Sung Y-K, Cho S-K, Kim D et al (2017) Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis. Rheumatol Int 37:975\u2013982. \n                    https:\/\/doi.org\/10.1007\/s00296-016-3649-2","journal-title":"Rheumatol Int"},{"key":"557_CR37","doi-asserted-by":"publisher","DOI":"10.2174\/1570163815666180515122834","author":"M Taeb","year":"2018","unstructured":"Taeb M, Jafarzadeh A, Mortazavi-Jahromi SS et al (2018) Effect of \u03b2-d-mannuronic acid (M2000) on oxidative stress enzymes\u2019 gene using healthy donor peripheral blood mononuclear cells for evaluating the anti-aging property. Curr Drug Discov Technol. \n                    https:\/\/doi.org\/10.2174\/1570163815666180515122834","journal-title":"Curr Drug Discov Technol"},{"key":"557_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.18773\/austprescr.2017.012.40:51","volume":"40","author":"TD Wilsdon","year":"2017","unstructured":"Wilsdon TD, Hill CL (2017) Managing the drug treatment of rheumatoid arthritis. Aust Prescr 40:51\u201358. \n                    https:\/\/doi.org\/10.18773\/austprescr.2017.012.40:51","journal-title":"Aust Prescr"},{"key":"557_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/OARRR.S32493","volume":"4","author":"M Yang","year":"2012","unstructured":"Yang M, Guo M (2012) Goals for rheumatoid arthritis: treating to target or treating to prevent? Open Access Rheumatol 4:81\u201386. \n                    https:\/\/doi.org\/10.2147\/OARRR.S32493","journal-title":"Open Access Rheumatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-018-00557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10787-018-00557-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-018-00557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T19:48:44Z","timestamp":1577908124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10787-018-00557-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1007\/s10787-018-00557-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}